Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Ahmad Alcheikh; Griffith B. Perkins; Phillippa A. Pucar; Amelia Cecchin; Cheng Sheng Chai; Matthew Tunbridge; Anouschka Akerman; Anupriya Aggarwal; Vanessa Milogiannakis; Stuart Turville; Sharon Allen; Pravin Hissaria; Tatjana Banovic; P. Toby Coates; David M. Ross

doi:10.1038/s41408-023-00824-8

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Ahmad Alcheikh, Griffith B. Perkins, Phillippa A. Pucar, Amelia Cecchin, Cheng Sheng Chai, Matthew Tunbridge, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Stuart Turville, Sharon Allen, Pravin Hissaria, Tatjana Banovic, P. Toby Coates, David M. Ross

College of Medicine and Public Health

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

33 Downloads (Pure)

Abstract

Dear Editor,

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm associated with inflammatory manifestations including fibrosis and constitutional symptoms. The standard treatment for symptomatic MF is ruxolitinib, a JAK1/2 inhibitor (JAKi) that antagonizes cytokine receptor signalling. JAK-dependent cytokine signals are integral to an effective inflammatory response and ruxolitinib treatment is accompanied by an increased risk of infection, including reactivation of varicella zoster virus and tuberculosis. Individuals with advanced MF have an increased risk of severe COVID-19, and impaired response to vaccination.

In response to the COVID-19 pandemic, Australia implemented strict isolation measures. Negligible community transmission of SARS-CoV-2 until November 2021 in South Australia provided the opportunity to assess vaccine responses with minimal interference from natural infection...

Original language	English
Article number	50
Number of pages	4
Journal	Blood Cancer Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00824-8
Publication status	Published - 10 Apr 2023

Keywords

Adaptive immunity
Infectious diseases
Myeloproliferative disease
Preventive medicine
T cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-023-00824-8Licence: CC BY

Final published versionFinal published version, 1.18 MBLicence: CC BY

Cite this

Alcheikh, A., Perkins, G. B., Pucar, P. A., Cecchin, A., Chai, C. S., Tunbridge, M., Akerman, A., Aggarwal, A., Milogiannakis, V., Turville, S., Allen, S., Hissaria, P., Banovic, T., Coates, P. T., & Ross, D. M. (2023). Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients. Blood Cancer Journal, 13(1), Article 50. https://doi.org/10.1038/s41408-023-00824-8

@article{dfb4142b651848649e74f901aebd69c7,

title = "Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients",

abstract = "Dear Editor,Myelofibrosis (MF) is a clonal myeloproliferative neoplasm associated with inflammatory manifestations including fibrosis and constitutional symptoms. The standard treatment for symptomatic MF is ruxolitinib, a JAK1/2 inhibitor (JAKi) that antagonizes cytokine receptor signalling. JAK-dependent cytokine signals are integral to an effective inflammatory response and ruxolitinib treatment is accompanied by an increased risk of infection, including reactivation of varicella zoster virus and tuberculosis. Individuals with advanced MF have an increased risk of severe COVID-19, and impaired response to vaccination.In response to the COVID-19 pandemic, Australia implemented strict isolation measures. Negligible community transmission of SARS-CoV-2 until November 2021 in South Australia provided the opportunity to assess vaccine responses with minimal interference from natural infection...",

keywords = "Adaptive immunity, Infectious diseases, Myeloproliferative disease, Preventive medicine, T cells",

author = "Ahmad Alcheikh and Perkins, {Griffith B.} and Pucar, {Phillippa A.} and Amelia Cecchin and Chai, {Cheng Sheng} and Matthew Tunbridge and Anouschka Akerman and Anupriya Aggarwal and Vanessa Milogiannakis and Stuart Turville and Sharon Allen and Pravin Hissaria and Tatjana Banovic and Coates, {P. Toby} and Ross, {David M.}",

year = "2023",

month = apr,

day = "10",

doi = "10.1038/s41408-023-00824-8",

language = "English",

volume = "13",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Alcheikh, A, Perkins, GB, Pucar, PA, Cecchin, A, Chai, CS, Tunbridge, M, Akerman, A, Aggarwal, A, Milogiannakis, V, Turville, S, Allen, S, Hissaria, P, Banovic, T, Coates, PT & Ross, DM 2023, 'Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients', Blood Cancer Journal, vol. 13, no. 1, 50. https://doi.org/10.1038/s41408-023-00824-8

TY - JOUR

T1 - Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

AU - Alcheikh, Ahmad

AU - Perkins, Griffith B.

AU - Pucar, Phillippa A.

AU - Cecchin, Amelia

AU - Chai, Cheng Sheng

AU - Tunbridge, Matthew

AU - Akerman, Anouschka

AU - Aggarwal, Anupriya

AU - Milogiannakis, Vanessa

AU - Turville, Stuart

AU - Allen, Sharon

AU - Hissaria, Pravin

AU - Banovic, Tatjana

AU - Coates, P. Toby

AU - Ross, David M.

PY - 2023/4/10

Y1 - 2023/4/10

N2 - Dear Editor,Myelofibrosis (MF) is a clonal myeloproliferative neoplasm associated with inflammatory manifestations including fibrosis and constitutional symptoms. The standard treatment for symptomatic MF is ruxolitinib, a JAK1/2 inhibitor (JAKi) that antagonizes cytokine receptor signalling. JAK-dependent cytokine signals are integral to an effective inflammatory response and ruxolitinib treatment is accompanied by an increased risk of infection, including reactivation of varicella zoster virus and tuberculosis. Individuals with advanced MF have an increased risk of severe COVID-19, and impaired response to vaccination.In response to the COVID-19 pandemic, Australia implemented strict isolation measures. Negligible community transmission of SARS-CoV-2 until November 2021 in South Australia provided the opportunity to assess vaccine responses with minimal interference from natural infection...

AB - Dear Editor,Myelofibrosis (MF) is a clonal myeloproliferative neoplasm associated with inflammatory manifestations including fibrosis and constitutional symptoms. The standard treatment for symptomatic MF is ruxolitinib, a JAK1/2 inhibitor (JAKi) that antagonizes cytokine receptor signalling. JAK-dependent cytokine signals are integral to an effective inflammatory response and ruxolitinib treatment is accompanied by an increased risk of infection, including reactivation of varicella zoster virus and tuberculosis. Individuals with advanced MF have an increased risk of severe COVID-19, and impaired response to vaccination.In response to the COVID-19 pandemic, Australia implemented strict isolation measures. Negligible community transmission of SARS-CoV-2 until November 2021 in South Australia provided the opportunity to assess vaccine responses with minimal interference from natural infection...

KW - Adaptive immunity

KW - Infectious diseases

KW - Myeloproliferative disease

KW - Preventive medicine

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85151979170&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00824-8

DO - 10.1038/s41408-023-00824-8

M3 - Letter

C2 - 37032391

AN - SCOPUS:85151979170

SN - 2044-5385

VL - 13

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 50

ER -

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this